Menu Back toSession-0703-Development-of-Biosimilars-in-China-Interpretation-of-Biosimilar-Guidance-Opportunities-and-Challenges-I
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
The 7th DIA China Annual Meeting
Session 0703 Development of Biosimilars in China: Interpretation of Biosimilar Guidance, Opportunities and Challenges - I
- Co-founder and CEO
- BJ Bioscience Inc., China
EMA & Biosimilar update Trends and developments in marketing authorisation applications, scientific advice procedures and policies
Evangelos Kotzagiorgis, MPharm, MS
- Scientific Administrator, Quality of Medicines, Human Medicines Evaluation Div
- European Medicines Agency, Netherlands
Global mAb Biosimilar Industry Challenges and Opportunities from Policy to Reality
- Genor BioPharm, Walvax Bio Group, China